Bayesian Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bayesian Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,087	Closed	-$307K	–	665
2024 Q4	$307K	Buy	+6,087	New	+$319K	0.04%	481
2024 Q2	–	Sell	-27,923	Closed	-$703K	–	803
2024 Q1	$703K	Buy	+27,923	New	+$660K	0.07%	370
2023 Q4	–	Sell	-12,409	Closed	-$338K	–	798
2023 Q3	$338K	Buy	+12,409	New	+$359K	0.04%	446
2020 Q4	–	Sell	-28,057	Closed	-$488K	–	487
2020 Q3	$488K	Buy	+28,057	New	+$447K	0.12%	231
2020 Q2	–	Sell	-19,400	Closed	-$231K	–	562
2020 Q1	$231K	Buy	19,400 +6,701	+53%	+$82.9K	0.05%	541
2019 Q4	$154K	Buy	+12,699	New	+$177K	0.03%	552
2017 Q4	–	Sell	-14,700	Closed	-$284K	–	577
2017 Q3	$284K	Buy	+14,700	New	+$219K	0.07%	376

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bayesian Capital Management's CORT Position: Q1 2025 in Review

Bayesian Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 6,087 shares — an estimated $307K sold.

Bayesian Capital Management first reported a position in CORT in Q3 2017 and held it in 7 quarters. The position peaked at $703K in Q1 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

Bayesian Capital Management reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 6,087 Corcept Therapeutics shares in Q1 2025, an estimated $307K.
Bayesian Capital Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 7 quarters.
Bayesian Capital Management's Corcept Therapeutics position peaked at $703K in Q1 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.